The multifactorial nature of Alzheimer's disease necessitates the development of agents able to interfere with different relevant targets. A series of 22 tailored chromanones was conceptualized, synthesized, and subjected to biological evaluation. We identified one representative bearing a linker-connected azepane moiety (compound ) with balanced pharmacological properties. Compound exhibited inhibitory activities against human acetyl-, butyrylcholinesterase and monoamine oxidase-B, as well as high affinity to both the σ and σ receptors. Our study provides a framework for the development of further chromanone-based multineurotarget agents.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667544PMC
http://dx.doi.org/10.1021/acsptsci.2c00097DOI Listing

Publication Analysis

Top Keywords

chemotype chromanones
4
chromanones privileged
4
privileged scaffold
4
scaffold multineurotarget
4
multineurotarget anti-alzheimer
4
anti-alzheimer agents
4
agents multifactorial
4
multifactorial nature
4
nature alzheimer's
4
alzheimer's disease
4

Similar Publications

The Chemotype of Chromanones as a Privileged Scaffold for Multineurotarget Anti-Alzheimer Agents.

ACS Pharmacol Transl Sci

November 2022

Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany.

The multifactorial nature of Alzheimer's disease necessitates the development of agents able to interfere with different relevant targets. A series of 22 tailored chromanones was conceptualized, synthesized, and subjected to biological evaluation. We identified one representative bearing a linker-connected azepane moiety (compound ) with balanced pharmacological properties.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!